Improved functional ability in patients with rheumatoid arthritis - Longterm treatment with leflunomide versus sulfasalazine

Journal of Rheumatology

Volumn 28, Issue 9, 2001, Pages 1983-1991

  Kalden, J R ^a   Scott, D L ^a   Smolen, J S ^a   Schattenkirchner, M ^a   Rozman, B ^a   Williams, B D ^a   Kvien, T K ^a   Jones, P ^a   Williams, R B ^a   Oed, C ^a   Rosenburg, R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antirheumatic agents; Clinical trials; Phase III; Quality of life; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TRIAMCINOLONE;

ADULT; ALOPECIA; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEW ZEALAND; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SOUTH AFRICA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOXAZOLES; LONG-TERM CARE; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; PROBABILITY; PROGNOSIS; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034877904     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
2. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials
3. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
4. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis
5. Effects of leflunomide on immune responses and models of inflammation
6. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans
7. Mechanism of action of leflunomide in rheumatoid arthritis
8. Methotrexate and radiographic disease progression in patients with rheumatoid arthritis
9. The role of T-lymphocytes and cytokines in rheumatoid arthritis
10. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans
11. Effects of leflunomide on early T-cell signaling and cell cycle commitment
12. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-k B activation and gene expression
13. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled, phase II study
14. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
15. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
16. Measurement of patient outcome in arthritis
17. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study
18. Comparison of standard and alternative Health Assessment Questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis
19. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome
20. Characteristics of rheumatoid arthritis patients: Who participates in long-term research and who drops out?
21. Measuring health status in arthritis. The Arthritis Impact Measurement Scales
22. The Sickness Impact Profile: Development and final revision of a health status measure
23. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial
24. Efficacy of cyclosporin A in rheumatoid arthritis: Long-term follow-up data and the effect on quality of life
25. Function and health-related quality of life. Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis
26. Are we making the most of the Stanford Health Assessment Questionnaire?
27. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles
28. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective
29. Disability scores in DMARD trials. What is a clinically important change?
30. Sulfasalazine in early rheumatoid arthritis
31. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine
32. Renal effects of leflunomide compared with other agents used to treat rheumatoid arthritis